Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Correspondence to Dr Hideo Ohuchi, Department of Paediatric Cardiology, National Cerebral and Cardiovascular Centre, 5-7-1, Fujishiro-dai, Suita, Osaka 565-8565, Japan; hohuchi{at}hsp.ncvc.go.jp ...

Abstract: This paper proposes a novel mathematical model that quantitatively defines the relationships between the arterial oxygen saturation (SaO2), the arterial partial pressure of oxygen (PaO2) and ...

Methods: To achieve these objectives, we included 14 healthy participants aged 23-39 years in the study, and we induced several stable plateaus of arterial oxygen saturation (SaO2) ranging from ...

Abstract: The paper proposes the diagnosis of Sleep Apnea Hypopnea Syndrome (SAHS) only using snore sound and SaO2 signals. The time-frequency characteristics of snore sound signal are extracted to ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

来自国际研究团队的系统性综述揭示：心肺运动试验(CPET)能显著提升肥厚型心肌病(HCM)患者的心功能评估灵敏度。通过对12,914 ...

这篇研究通过分析Fontan循环患者运动时的峰值外周静脉压（PPVP）与峰值摄氧量（PVO2）关系，揭示了静脉-静脉侧支（VVCs）的双重作用：低PVO2时缓冲中心静脉压，高PVO2时加重静脉负荷，为临床评估VVCs的血流动力学影响提供了新视角。 Fontan手术的预后近年来因 ...

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...

Serious hidden hypoxemia — defined as an SaO2 less than 88% despite an SpO2 of 92% or greater — occurred in 0.6% of the critically ill Asian patients studied. Hypoxemia went undetected in 0.8% of ...